Focus: AskBio is a 5,000+ employee biotech company founded in 2020, headquartered in Durham, NC, focused on cellular and protein-based therapies with a pipeline concentrated in rare genetic and neurodegenerative diseases.
Profile data last refreshed 7h ago · AI intelligence enriched 2w ago
Stable — net +2 jobs in 30d
6 added, 4 removed. Backfill posture.
Best fit for R&D scientists, translational researchers, and clinical professionals betting on rare disease/gene therapy IP, but requires patience on cash-burn trajectory and approval timelines.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for AskBio
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from AskBio's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Based on last 4 crawl cycles
Recent peer-reviewed publications with author affiliations at this company
AB-1002 gene therapy expressing active protein phosphatase inhibitor-1 in heart failure: Rationale and study design of the GenePHIT trial.
A Review of the Challenge of Pre-Existing Humoral Immunity in Adeno-Associated Virus Gene Therapy and Potential Solutions.
Showing 5 of 10 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo